Your search for mepolizumab returned 118 results

Mepolizumab 100mg/vial; lyophilized pwd for SC inj after reconstitution; or 100mg/mL, 40mg/0.4mL; soln for SC inj; preservative-free.

Teplizumab-mzwv 1mg/mL; soln for IV inj after dilution; preservative-free.

Vedolizumab 300mg; per vial; lyophilized pwd for IV infusion after reconstitution and dilution; preservative-free.

Chupp, GL et al. “Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.” DOI: http://dx.doi.org/10.1016/S2213-2600(17)30125-X

GlaxoSmithKline announced positive results from the pivotal phase 3 study of mepolizumab in the treatment of patients with hypereosinophilic syndrome (HES). HES is a rare group of inflammatory disorders characterized by persistent eosinophilia that can potentially lead to inflammation, organ damage, and possibly death if left untreated.  The 32-week, double-blind, placebo-controlled phase 3 study evaluated…

Treatment with mepolizumab was associated with a significant reduction in asthma exacerbations and oral corticosteroid use in patients with severe eosinophilic asthma.

In a real-world setting, mepolizumab therapy significantly reduced the rate of asthma exacerbations and their related costs.

The primary outcome was to compare dupilumab, benralizumab, and mepolizumab in patients with at least 2 pre-index exacerbations.

The FDA previously granted Fast Track and Orphan Drug designations to mepolizumab for the treatment of HES.

The phase 3 SYNAPSE clinical trial evaluated the efficacy of mepolizumab in improving sense of smell in patients with chronic rhinosinusitis with nasal polyps.